Omnitrope approval raises concerns in biotech industry

The FDA's recent approval of a generic version of Pfizer's biotech drug Genotropin has raised concerns in the industry about a possible change in approval of copies of biotech drugs. The biotech industry has long argued its products are too complex to be copied safely, and Congress and the FDA hesitated allowing copies; but the generics industry is pushing for a more flexible policy.

View Full Article in:

San Jose Mercury News (Calif.) (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA